ETHYL 5-HYDROXY-TETRAHYDRO-PYRAN-2-CARBOXYLATE, 95.0%, 1g

3-(4-Fluorophenyl)-1-methyl-1H-pyrazol-5-amine, 95.0%, 250mg

Sphos, min. 98%, 5 g, glass packaging

3-methoxy-4-[2-(1-piperidinyl)ethoxy]benzaldehyde hydrochloride, 95.0%, 1g

2-(3-(Benzyloxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 97%, 250mg

tert-Butyl 4-((2-bromo-4-fluorophenyl)amino)-4-cyanopiperidine-1-carboxylate, 98%, 1g

3-Bromo-2-chlorobenzoic acid, 95.0%, 1g

(S)-2-Amino-1,1,3-triphenylpropan-1-ol, 98%, 1g

4-Chloro-2-nitropyridine, 95.0%, 1g

(S)-4-(tert-Butyl)-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole, 95.0%, 100mg

Hybridisation vial PVC-coated, Height, 150 mm, 35 mm, 1 Piece

5-Methoxynicotinic acid, 97.0%, 5g

1-[(benzyloxy)carbonyl]-5,5-difluoropiperidine-3-carboxylic acid, 97.0%, 1g